BioAge Labs announces $75M common stock offering

BioAge Labs (BIOA) announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75M of shares of its common stock. All of the shares of common stock are being offered by BioAge. BioAge intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research, clinical and process development and manufacturing of its product candidates, including BGE-102 and further development of its NLRP3 and APJ programs, working capital, capital expenditures, reduction of indebtedness and for other general corporate purposes. Goldman Sachs & Co., Piper Sandler and Citigroup are acting as joint book-running managers for the proposed offering.